News

Precision Optics Corporation's Upcoming Financial Conference Call

Precision Optics Corporation's Upcoming Financial Conference Call

Precision Optics Corporation Announces Conference Call

Precision Optics Corporation, Inc. (Nasdaq: POCI), a pioneer in creating advanced optical instruments for medical and defense industries, has announced an exciting opportunity for stakeholders. On an upcoming Thursday, the company will conduct a conference call to discuss its financial results for the first quarter of fiscal year 2025.

Scheduled Date and Time

The conference call is set for a Thursday evening at 5:00 PM ET. The timing is designed to allow investors and interested parties to engage directly with the company’s leadership, gaining insights into its performance and strategic direction.

Financial Results Release

Precision Optics intends to share its financial results prior to the call, reflecting a commitment to transparency and shareholder communication. The company plans to file its quarterly report after market close on the same day as the call, providing stakeholders with timely information to understand its financial health.

Call-in and Webcast Details

For those who wish to partake in the call, numerous options are available. Interested listeners can join by dialling (844) 735-3662 or (412) 317-5705 to access the conference. Additionally, there will be a live webcast option for anyone preferring an online connection. Participants can find the webcast link on the company’s website when the date approaches.

Replay Information

In case you are unable to listen live, a replay of the conference call will be made available shortly after the event. The replay can be accessed until a designated date, ensuring that everyone has an opportunity to catch up on crucial company information.

About the Company

Founded in 1982, Precision Optics specializes in developing cutting-edge optical systems. The company focuses on serving the healthcare and defense sectors with its innovative micro-optics and 3D imaging technologies. Precision Optics supports medical device manufacturers by providing advanced imaging solutions required for minimally invasive surgeries.

Pioneering Solutions for the Future

The expertise of Precision Optics goes beyond medical applications. The company is also paving the way for defense and aerospace industries, where high-quality optical components are essential. Their commitment to innovation positions Precision Optics as a go-to partner for industries requiring precise optical solutions.

Contact Information

For further inquiries, Precision Optics welcomes contacting their main office located at:

PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Relations

For investor relations, Precision Optics encourages reaching out to Lytham Partners, where Robert Blum is ready to assist:

LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
Email: poci@lythampartners.com

Frequently Asked Questions

What is the date of the conference call?

The conference call is scheduled for a Thursday at 5:00 PM ET.

How can I access the conference call?

Participants can join the call by phone or through a live webcast on the company’s website.

What financial results will be discussed?

The call will cover the first quarter fiscal year 2025 financial results.

Will there be a replay available?

Yes, a replay of the call will be available for a set period after the live event.

Where can I find more information about Precision Optics?

Additional information about the company can be found on their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading